CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease
Executive Summary
The Centers for Medicare and Medicaid Services has decided not to proceed with a national coverage determination for erythropoiesis-stimulating agents in patients with chronic kidney disease, according to a proposed decision memo released March 16.
You may also be interested in...
Genetic Testing, But No Drugs, On Revised List Of Potential Medicare NCD Topics
CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.
Targeted Drugs With Companion Dx May Draw Medicare NCD Interest – Phurrough
Targeted drugs indicated for use with companion diagnostics raise the kind of reimbursement concerns that may make them eligible topics for a Medicare national coverage determination, Steve Phurrough, former director of the Centers for Medicare and Medicaid Services coverage and analysis group, suggests.
Targeted Drugs With Companion Dx May Draw Medicare NCD Interest – Phurrough
Targeted drugs indicated for use with companion diagnostics raise the kind of reimbursement concerns that may make them eligible topics for a Medicare national coverage determination, Steve Phurrough, former director of the Centers for Medicare and Medicaid Services coverage and analysis group, suggests.